ME02182B - TERAPEUTSKA KOMBINACIJA KOJA SADRŽI DOLUTEGRAVIR, ABAKAVIR l LAMIVUDIN - Google Patents
TERAPEUTSKA KOMBINACIJA KOJA SADRŽI DOLUTEGRAVIR, ABAKAVIR l LAMIVUDINInfo
- Publication number
- ME02182B ME02182B MEP-2015-106A MEP10615A ME02182B ME 02182 B ME02182 B ME 02182B ME P10615 A MEP10615 A ME P10615A ME 02182 B ME02182 B ME 02182B
- Authority
- ME
- Montenegro
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- compound
- intended
- Prior art date
Links
- UGWQMIXVUBLMAH-IVVFTGHFSA-N [(1s,4r)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol;4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 UGWQMIXVUBLMAH-IVVFTGHFSA-N 0.000 title 1
- RHWKPHLQXYSBKR-BMIGLBTASA-N dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 title 1
- 229960002542 dolutegravir Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 claims 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 claims 1
- 108010018763 Biotin carboxylase Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (5)
1. Spoj, naznačen time što je spoj Formule (I),ili njegova farmaceutski prihvatljiva sol.
2. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu farmaceutski prihvatljivu sol, kao i farmaceutski prihvatljivu pomoćnu tvar, razrjeđivač ili podlogu.
3. Spoj u skladu s patentnim zahtjevom 1 ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u postupku liječenja bolesti, stanja ili poremećaja koje se modulira inhibiranjem jednog ili više enzima acetil-CoA karboksilaza.
4. Spoj u skladu s patentnim zahtjevom 1 ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u postupku u skladu s patentnim zahtjevom 3, gdje je bolest, stanje ili poremećaj dijabetes tip 2, poremećaji povezani s dijabetesom, nealkoholna bolest masne jetre (NAFLD) ili jetrena otpornost na inzulin.
5. Spoj u skladu s patentnim zahtjevom 1 ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u postupku u skladu s patentnim zahtjevom 3, gdje je bolest, stanje ili poremećaj dijabetes tip 2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29858910P | 2010-01-27 | 2010-01-27 | |
| PCT/US2011/022219 WO2011094150A1 (en) | 2010-01-27 | 2011-01-24 | Antiviral therapy |
| EP11737484.3A EP2531027B1 (en) | 2010-01-27 | 2011-01-24 | Therapeutic combination comprising dolutegravir, abacavir and lamivudine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02182B true ME02182B (me) | 2015-10-20 |
Family
ID=44319704
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-106A ME02182B (me) | 2010-01-27 | 2011-01-24 | TERAPEUTSKA KOMBINACIJA KOJA SADRŽI DOLUTEGRAVIR, ABAKAVIR l LAMIVUDIN |
| MEP-2018-131A ME03058B (me) | 2010-01-27 | 2011-01-24 | Antivirusna terapija |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2018-131A ME03058B (me) | 2010-01-27 | 2011-01-24 | Antivirusna terapija |
Country Status (45)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA105556C2 (uk) | 2010-01-27 | 2014-05-26 | Віів Гелскер Компані | Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами |
| US10004721B2 (en) | 2012-10-23 | 2018-06-26 | Cipla Limited | Pharmaceutical antiretroviral composition |
| CA2893843C (en) | 2012-12-21 | 2018-09-04 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| EP2956123A1 (en) | 2013-02-18 | 2015-12-23 | ratiopharm GmbH | Solid pharmaceutical dosage form of dolutegravir |
| EP2767272A1 (en) * | 2013-02-18 | 2014-08-20 | Ratiopharm GmbH | Solid pharmaceutical dosage form of dolutegravir |
| NO2865735T3 (me) | 2013-07-12 | 2018-07-21 | ||
| DK3019503T3 (da) | 2013-07-12 | 2017-11-20 | Gilead Sciences Inc | Polycykliske-carbamoylpyridon-forbindelser og anvendelse deraf til behandling af hiv-infektioner |
| MX367057B (es) | 2013-09-27 | 2019-08-02 | Merck Sharp & Dohme | Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih. |
| WO2015140569A1 (en) | 2014-03-20 | 2015-09-24 | Cipla Limited | Pharmaceutical composition |
| EP3151920B1 (en) | 2014-06-04 | 2025-08-06 | Sanford-Burnham Medical Research Institute | Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy |
| NO2717902T3 (me) | 2014-06-20 | 2018-06-23 | ||
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| WO2016016279A1 (en) | 2014-07-29 | 2016-02-04 | Lek Pharmaceuticals D.D. | Novel hydrates of dolutegravir sodium |
| TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| TR201905009T4 (tr) | 2015-04-02 | 2019-05-21 | Gilead Sciences Inc | Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları. |
| WO2017029225A1 (en) * | 2015-08-14 | 2017-02-23 | Sandoz Ag | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz |
| WO2017205585A1 (en) * | 2016-05-27 | 2017-11-30 | Viiv Healthcare Company | Combinations and uses treatments thereof |
| WO2018028841A1 (en) * | 2016-08-12 | 2018-02-15 | Sandoz Ag | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz |
| WO2018042332A1 (en) * | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
| WO2019016679A1 (en) * | 2017-07-18 | 2019-01-24 | Viiv Healthcare Company | Combination drug therapy |
| JP2020528413A (ja) * | 2017-07-21 | 2020-09-24 | ヴィーブ ヘルスケア カンパニー | Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン |
| KR20260015342A (ko) | 2017-07-21 | 2026-02-02 | 비이브 헬쓰케어 컴퍼니 | Hib 감염 및 aids를 치료하기 위한 요법 |
| AU2018347990B2 (en) * | 2017-10-13 | 2021-09-09 | Viiv Healthcare Company | Bi-layer pharmaceutical tablet formulation |
| IL286328B1 (en) | 2019-03-22 | 2026-04-01 | Gilead Sciences Inc | Tricyclic bridging compounds of carbamoylpyridone and their pharmaceutical use |
| CN114901363A (zh) * | 2020-01-09 | 2022-08-12 | 华盛顿大学 | 长效治疗剂组合物及其方法 |
| CR20220418A (es) | 2020-02-24 | 2022-10-10 | Gilead Sciences Inc | Compuestos tetracíclicos para el tratamiento de infecciones por vih |
| CA3192145A1 (en) | 2020-09-30 | 2022-04-07 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| JP7591155B2 (ja) | 2021-01-19 | 2024-11-27 | ギリアード サイエンシーズ， インコーポレイテッド | 置換ピリドトリアジン化合物及びその使用 |
| CN114230579A (zh) * | 2021-11-12 | 2022-03-25 | 南京艾迪医药科技有限公司 | 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物 |
| WO2023164293A1 (en) * | 2022-02-28 | 2023-08-31 | Jericho Sciences, Llc | Methods for viral infections |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7119202B1 (en) | 1989-02-08 | 2006-10-10 | Glaxo Wellcome Inc. | Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties |
| US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
| GB9009861D0 (en) | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
| ZA923641B (en) | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
| GB9111902D0 (en) | 1991-06-03 | 1991-07-24 | Glaxo Group Ltd | Chemical compounds |
| GB9204015D0 (en) | 1992-02-25 | 1992-04-08 | Wellcome Found | Therapeutic nucleosides |
| US5663169A (en) | 1992-08-07 | 1997-09-02 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
| IL106507A (en) | 1992-08-07 | 1997-11-20 | Merck & Co Inc | Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type |
| GB9402161D0 (en) | 1994-02-04 | 1994-03-30 | Wellcome Found | Chloropyrimidine intermediates |
| IL113432A (en) | 1994-04-23 | 2000-11-21 | Glaxo Group Ltd | Process for the diastereoselective synthesis of nucleoside analogues |
| UA49803C2 (uk) | 1994-06-03 | 2002-10-15 | Дж.Д. Сьорль Енд Ко | Спосіб лікування ретровірусних інфекцій |
| MY115461A (en) | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
| US5914332A (en) | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5849911A (en) | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
| WO1997049411A1 (en) * | 1996-06-25 | 1997-12-31 | Glaxo Group Limited | Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5965729A (en) | 1997-02-05 | 1999-10-12 | Merck & Co., Inc. | Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent |
| GB9709945D0 (en) | 1997-05-17 | 1997-07-09 | Glaxo Group Ltd | A novel salt |
| US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| GB9717928D0 (en) | 1997-08-22 | 1997-10-29 | Glaxo Group Ltd | Process for the enatioselective hydrolysis of n-derivatised lactams |
| GB9721780D0 (en) | 1997-10-14 | 1997-12-10 | Glaxo Group Ltd | Process for the synthesis of chloropurine intermediates |
| US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| US6087383A (en) | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
| GB9805898D0 (en) | 1998-03-20 | 1998-05-13 | Glaxo Group Ltd | Process for the sythesis of hiv protease inhibitors |
| AU3366899A (en) | 1998-03-27 | 1999-10-18 | Regents Of The University Of California, The | Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors |
| UA72207C2 (uk) | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
| GB9809213D0 (en) * | 1998-04-29 | 1998-07-01 | Glaxo Group Ltd | Pharmaceutical compositions |
| GB9815567D0 (en) | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| CA2398640C (en) | 2000-01-31 | 2011-06-14 | Cook Biotech Incorporated | Stent valves and uses of same |
| EE05400B1 (et) | 2001-04-10 | 2011-04-15 | Pfizer Inc. | Prasoolderivaadid, neid v?i nende farmatseutiliselt vastuv?etavaid sooli, solvaate v?i derivaate sisaldavad farmatseutilised kompositsioonid, nende kasutamine ning meetodid nende valmistamiseks |
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| US7638522B2 (en) * | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
| JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| AR040242A1 (es) | 2002-06-04 | 2005-03-23 | Glaxo Group Ltd | Composiciones farmaceuticas |
| DE60303131T2 (de) | 2002-06-27 | 2006-07-20 | Medivir Ab | Synergistische wechselwirkung von abacavir und alovudin |
| EA015145B1 (ru) * | 2003-01-14 | 2011-06-30 | Джилид Сайэнс, Инк. | Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| EP1720856B1 (en) | 2004-02-11 | 2013-08-14 | GlaxoSmithKline LLC | Hiv integrase inhibitors |
| JP4285353B2 (ja) | 2004-03-05 | 2009-06-24 | 清水建設株式会社 | 化学物質放散度評価方法 |
| ATE411030T1 (de) * | 2004-04-14 | 2008-10-15 | Gilead Sciences Inc | Phosphonatanaloga von hiv- integrasehemmerverbindungen |
| EP2229945A1 (en) * | 2004-05-21 | 2010-09-22 | Japan Tobacco, Inc. | Combinations comprising a 4-isoquinolone derivative and anti-HIV agents |
| US7176196B2 (en) | 2004-05-28 | 2007-02-13 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| DE602005025977D1 (de) | 2004-08-23 | 2011-03-03 | Teva Pharma | Kristalline form des ibandronat-natriums und herstellungsverfahren dafür |
| WO2006024668A1 (en) | 2004-09-02 | 2006-03-09 | Janssen Pharmaceutica N.V. | Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile |
| DE602005011031D1 (en) | 2004-09-17 | 2008-12-24 | Idenix Pharmaceuticals Inc | Phosphoindole als hiv-inhibitoren |
| US7250421B2 (en) | 2005-01-31 | 2007-07-31 | University Of Georgia Research Foundation, Inc. | Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase |
| EP1853604A4 (en) | 2005-03-04 | 2010-02-24 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| CN101212903B (zh) * | 2005-04-28 | 2013-07-24 | 史密丝克莱恩比彻姆公司 | 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物 |
| PT1874117E (pt) | 2005-04-28 | 2013-10-17 | Shionogi & Co | Derivado policíclico de carbamoílpiridona possuindo actividade inibidora de hiv-integrasse |
| WO2006129134A1 (en) | 2005-06-01 | 2006-12-07 | Bioalliance Pharma | Synergic combinations comprising a styrylquinoline compound and other hiv infection therapeutic agents |
| CN101336107A (zh) * | 2005-12-30 | 2008-12-31 | 吉里德科学公司 | 改善hiv整合酶抑制剂的药物动力学的方法 |
| BRPI0620865A2 (pt) | 2005-12-30 | 2011-11-29 | Gilead Sciences Inc | métodos para melhorar a farmacocinética de inibidores das integrases do hiv |
| CA2636436C (en) * | 2006-01-20 | 2014-04-01 | Tibotec Pharmaceuticals Ltd. | Long term treatment of hiv- infection with tmc278 |
| US20080039428A1 (en) | 2006-06-29 | 2008-02-14 | Panacos Pharmaceuticals, Inc. | Antiretroviral combination therapy |
| AU2007275690B2 (en) | 2006-07-21 | 2013-01-17 | Gilead Sciences, Inc. | Antiviral protease inhibitors |
| ES2488922T3 (es) | 2006-09-29 | 2014-09-01 | Idenix Pharmaceuticals, Inc. | Fosfoindoles enantiómeramente puros como inhibidores del HIV |
| EP4403221A3 (en) | 2007-02-23 | 2024-10-09 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| WO2008103899A1 (en) | 2007-02-23 | 2008-08-28 | Auspex Pharmaceuticals, Inc. | Preparation and utility of non-nucleoside reverse transcriptase inhibitors |
| CN101784532B (zh) | 2007-06-29 | 2014-10-22 | 韩国化学研究院 | Hiv逆转录酶抑制剂 |
| KR20100041798A (ko) | 2007-06-29 | 2010-04-22 | 한국화학연구원 | 신규 ｈｉｖ 역전사효소 억제제 |
| CN101796040A (zh) | 2007-07-06 | 2010-08-04 | 吉里德科学公司 | 治疗剂的药代动力学特性调节剂 |
| US8426434B2 (en) * | 2007-07-12 | 2013-04-23 | Tibotec Pharmaceuticals Ltd. | Crystalline form of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile |
| WO2009058923A1 (en) | 2007-10-31 | 2009-05-07 | Smithkline Beecham Corporation | Ccr5 antagonists as therapeutic agents |
| JP2011502998A (ja) | 2007-11-01 | 2011-01-27 | ザ ユーエイビー リサーチ ファウンデイション | ウイルス感染の治療および予防 |
| US8108055B2 (en) | 2007-12-28 | 2012-01-31 | Larry Wong | Method, system and apparatus for controlling an electrical device |
| EP2250185A4 (en) * | 2008-01-03 | 2011-11-16 | Virochem Pharma Inc | NEW LUPANDERIVATE |
| EP2240504A1 (en) | 2008-01-03 | 2010-10-20 | Virochem Pharma Inc. | Novel c-21-keto lupane derivatives preparation and use thereof |
| PT2231628E (pt) | 2008-01-04 | 2015-12-29 | Gilead Sciences Inc | Inibidores de citocromo p450 |
| AU2009214779A1 (en) | 2008-02-14 | 2009-08-20 | Virochem Pharma Inc. | Novel 17beta lupane derivatives |
| WO2009148600A2 (en) * | 2008-06-06 | 2009-12-10 | Concert Pharmaceuticals, Inc. | Deuterated lysine-based compounds |
| SI2320908T1 (sl) * | 2008-07-25 | 2014-05-30 | Viiv Healthcare Company | Predzdravila dolutegravirja |
| KR101678563B1 (ko) | 2008-12-11 | 2016-11-22 | 비이브 헬쓰케어 컴퍼니 | 카르바모일피리돈 ｈｉｖ 인테그라제 억제제를 위한 제조방법 및 중간체 |
| KR101733625B1 (ko) * | 2008-12-11 | 2017-05-10 | 시오노기세야쿠 가부시키가이샤 | 카르바모일피리돈 ｈｉｖ 인테그라제 억제제 및 중간체의 합성 |
| UA105556C2 (uk) | 2010-01-27 | 2014-05-26 | Віів Гелскер Компані | Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами |
| GB201006038D0 (en) | 2010-04-12 | 2010-05-26 | Unilever Plc | Improvements relating to antiviral compositions |
| CN103402516B (zh) | 2010-06-17 | 2018-01-30 | 富津世生物技术有限公司 | 用作抗病毒药物的化合物、组合物及使用方法 |
| CA2832066C (en) | 2011-04-01 | 2023-04-18 | The Medicines Company | Short-acting dihydropyridines (clevidipine) for use in reducing stroke damage |
-
2011
- 2011-01-24 UA UAA201209253A patent/UA105556C2/uk unknown
- 2011-01-24 MA MA35145A patent/MA34002B1/fr unknown
- 2011-01-24 RS RS20150462A patent/RS54123B1/sr unknown
- 2011-01-24 ES ES16187411.0T patent/ES2688925T3/es active Active
- 2011-01-24 RS RS20180667A patent/RS57323B1/sr unknown
- 2011-01-24 PL PL16187411T patent/PL3127542T3/pl unknown
- 2011-01-24 JP JP2012551213A patent/JP2013518107A/ja active Pending
- 2011-01-24 SI SI201131492T patent/SI2932970T1/en unknown
- 2011-01-24 PL PL19151897.6T patent/PL3494972T3/pl unknown
- 2011-01-24 TR TR2018/07704T patent/TR201807704T4/tr unknown
- 2011-01-24 BR BR112012018670-1A patent/BR112012018670A2/pt not_active Application Discontinuation
- 2011-01-24 ME MEP-2015-106A patent/ME02182B/me unknown
- 2011-01-24 KR KR1020177017713A patent/KR20170078868A/ko not_active Ceased
- 2011-01-24 LT LTEP19151897.6T patent/LT3494972T/lt unknown
- 2011-01-24 MX MX2014014687A patent/MX367938B/es unknown
- 2011-01-24 HU HUE16187411A patent/HUE040554T2/hu unknown
- 2011-01-24 EA EA201690872A patent/EA032868B1/ru active Protection Beyond IP Right Term
- 2011-01-24 KR KR1020187018909A patent/KR101964923B1/ko active Active
- 2011-01-24 PH PH1/2012/501537A patent/PH12012501537A1/en unknown
- 2011-01-24 HR HRP20240168TT patent/HRP20240168T1/hr unknown
- 2011-01-24 SI SI201131593T patent/SI3127542T1/sl unknown
- 2011-01-24 SI SI201130539T patent/SI2531027T1/sl unknown
- 2011-01-24 NZ NZ627827A patent/NZ627827A/en unknown
- 2011-01-24 PL PL15164931T patent/PL2932970T3/pl unknown
- 2011-01-24 HU HUE19151897A patent/HUE065569T2/hu unknown
- 2011-01-24 MY MYPI2019000564A patent/MY202778A/en unknown
- 2011-01-24 WO PCT/US2011/022219 patent/WO2011094150A1/en not_active Ceased
- 2011-01-24 EP EP15164931.6A patent/EP2932970B1/en not_active Revoked
- 2011-01-24 EP EP11737484.3A patent/EP2531027B1/en not_active Revoked
- 2011-01-24 DK DK11737484.3T patent/DK2531027T3/en active
- 2011-01-24 EA EA201290583A patent/EA025176B1/ru active Protection Beyond IP Right Term
- 2011-01-24 AU AU2011209788A patent/AU2011209788C1/en active Active
- 2011-01-24 SG SG10201509476RA patent/SG10201509476RA/en unknown
- 2011-01-24 ES ES11737484.3T patent/ES2543066T3/es active Active
- 2011-01-24 US US13/575,380 patent/US20120295898A1/en not_active Abandoned
- 2011-01-24 SM SM20180594T patent/SMT201800594T1/it unknown
- 2011-01-24 LT LTEP15164931.6T patent/LT2932970T/lt unknown
- 2011-01-24 EA EA202190473A patent/EA202190473A3/ru unknown
- 2011-01-24 SG SG10201707183TA patent/SG10201707183TA/en unknown
- 2011-01-24 DK DK15164931.6T patent/DK2932970T3/en active
- 2011-01-24 EA EA201892277A patent/EA037601B1/ru active Protection Beyond IP Right Term
- 2011-01-24 CN CN201510619148.8A patent/CN105311033B/zh active Active
- 2011-01-24 MX MX2014014688A patent/MX367937B/es unknown
- 2011-01-24 HU HUE15164931A patent/HUE037812T2/hu unknown
- 2011-01-24 PT PT191518976T patent/PT3494972T/pt unknown
- 2011-01-24 SI SI201132101T patent/SI3494972T1/sl unknown
- 2011-01-24 KR KR1020167025050A patent/KR101883750B1/ko active Active
- 2011-01-24 PE PE2016000261A patent/PE20160180A1/es unknown
- 2011-01-24 MX MX2012008774A patent/MX2012008774A/es active IP Right Grant
- 2011-01-24 FI FIEP19151897.6T patent/FI3494972T3/fi active
- 2011-01-24 NZ NZ627826A patent/NZ627826A/en unknown
- 2011-01-24 MY MYPI2021001818A patent/MY207233A/en unknown
- 2011-01-24 PE PE2012001082A patent/PE20121524A1/es active IP Right Grant
- 2011-01-24 PT PT16187411T patent/PT3127542T/pt unknown
- 2011-01-24 CA CA2787691A patent/CA2787691C/en active Active
- 2011-01-24 NZ NZ601319A patent/NZ601319A/en unknown
- 2011-01-24 SM SM20180290T patent/SMT201800290T1/it unknown
- 2011-01-24 ME MEP-2018-131A patent/ME03058B/me unknown
- 2011-01-24 HU HUE11737484A patent/HUE026849T2/en unknown
- 2011-01-24 CA CA3060290A patent/CA3060290C/en active Active
- 2011-01-24 EP EP18161536.0A patent/EP3351249A1/en not_active Withdrawn
- 2011-01-24 EP EP16187411.0A patent/EP3127542B1/en active Active
- 2011-01-24 EP EP23214771.0A patent/EP4316599A3/en active Pending
- 2011-01-24 DK DK16187411.0T patent/DK3127542T3/en active
- 2011-01-24 PT PT151649316T patent/PT2932970T/pt unknown
- 2011-01-24 KR KR1020127022254A patent/KR101830715B1/ko active Active
- 2011-01-24 CN CN201180015114.8A patent/CN102791129B/zh active Active
- 2011-01-24 LT LTEP16187411.0T patent/LT3127542T/lt unknown
- 2011-01-24 PL PL11737484T patent/PL2531027T3/pl unknown
- 2011-01-24 SG SG2012053492A patent/SG182614A1/en unknown
- 2011-01-24 NO NO15164931A patent/NO2932970T3/no unknown
- 2011-01-24 MX MX2014014689A patent/MX356891B/es unknown
- 2011-01-24 DK DK19151897.6T patent/DK3494972T3/da active
- 2011-01-24 HR HRP20150770TT patent/HRP20150770T1/hr unknown
- 2011-01-24 CA CA2967453A patent/CA2967453C/en active Active
- 2011-01-24 PT PT117374843T patent/PT2531027E/pt unknown
- 2011-01-24 NZ NZ627824A patent/NZ627824A/en unknown
- 2011-01-24 SM SM20240063T patent/SMT202400063T1/it unknown
- 2011-01-24 ES ES15164931.6T patent/ES2670811T3/es active Active
- 2011-01-24 CA CA3003988A patent/CA3003988C/en active Active
- 2011-01-24 RS RS20181178A patent/RS57728B1/sr unknown
- 2011-01-24 RS RS20240189A patent/RS65183B1/sr unknown
- 2011-01-24 MY MYPI2012003346A patent/MY188334A/en unknown
- 2011-01-24 ES ES19151897T patent/ES2969969T3/es active Active
- 2011-01-24 AP AP2012006445A patent/AP3551A/xx active
- 2011-01-24 EP EP19151897.6A patent/EP3494972B1/en active Active
-
2012
- 2012-07-18 DO DO2012000205A patent/DOP2012000205A/es unknown
- 2012-07-18 IL IL221007A patent/IL221007A/en active IP Right Grant
- 2012-07-24 TN TNP2012000376A patent/TN2012000376A1/en unknown
- 2012-07-24 ZA ZA2012/05586A patent/ZA201205586B/en unknown
- 2012-07-26 CL CL2012002080A patent/CL2012002080A1/es unknown
- 2012-07-26 CO CO12125933A patent/CO6602152A2/es active IP Right Grant
- 2012-08-13 CR CR20120423A patent/CR20120423A/es unknown
- 2012-08-14 EC ECSP12012106 patent/ECSP12012106A/es unknown
-
2013
- 2013-06-06 HK HK18109751.0A patent/HK1250335A1/en unknown
-
2015
- 2015-05-13 US US14/710,952 patent/US20150238496A1/en not_active Abandoned
- 2015-07-17 CY CY20151100633T patent/CY1116509T1/el unknown
- 2015-07-24 SM SM201500177T patent/SMT201500177B/xx unknown
-
2016
- 2016-01-28 PH PH12016500195A patent/PH12016500195B1/en unknown
- 2016-01-29 JP JP2016015242A patent/JP2016145204A/ja active Pending
- 2016-03-18 US US15/073,728 patent/US20160199379A1/en not_active Abandoned
- 2016-04-18 IL IL245182A patent/IL245182B/en active IP Right Grant
- 2016-08-01 US US15/224,865 patent/US20160339033A1/en not_active Abandoned
- 2016-08-22 JP JP2016161610A patent/JP6268386B2/ja active Active
- 2016-12-01 US US15/366,566 patent/US20170119777A1/en not_active Abandoned
- 2016-12-01 US US15/366,442 patent/US10426780B2/en active Active
-
2017
- 2017-04-19 US US15/490,944 patent/US20170216284A1/en not_active Abandoned
- 2017-06-13 US US15/620,859 patent/US20170281636A1/en not_active Abandoned
- 2017-12-12 US US15/838,738 patent/US20180098992A1/en not_active Abandoned
-
2018
- 2018-01-31 IL IL257267A patent/IL257267B/en active IP Right Grant
- 2018-03-15 US US15/922,240 patent/US20180200254A1/en not_active Abandoned
- 2018-04-05 JP JP2018072861A patent/JP2018127473A/ja active Pending
- 2018-05-23 CY CY20181100548T patent/CY1120457T1/el unknown
- 2018-05-30 HR HRP20180855TT patent/HRP20180855T1/hr unknown
- 2018-09-26 HR HRP20181531TT patent/HRP20181531T1/hr unknown
- 2018-10-15 NO NO2018036C patent/NO2018036I1/no unknown
- 2018-10-15 FR FR18C1043C patent/FR18C1043I2/fr active Active
- 2018-10-16 CY CY2018029C patent/CY2018029I1/el unknown
- 2018-10-22 LT LTPA2018013C patent/LTC2932970I2/lt unknown
- 2018-10-23 CY CY181101087T patent/CY1121040T1/el unknown
- 2018-10-26 HU HUS1800042C patent/HUS1800042I1/hu unknown
- 2018-10-31 LU LU00090C patent/LUC00090I2/en unknown
- 2018-11-26 PH PH12018502489A patent/PH12018502489A1/en unknown
-
2019
- 2019-06-07 JP JP2019106635A patent/JP2019167371A/ja active Pending
- 2019-06-26 IL IL267658A patent/IL267658B/en active IP Right Grant
-
2020
- 2020-03-31 US US16/835,733 patent/US11234985B2/en active Active
-
2021
- 2021-02-26 JP JP2021030306A patent/JP7724619B2/ja active Active
- 2021-04-01 IL IL281959A patent/IL281959B/en unknown
- 2021-07-14 DO DO2021000147A patent/DOP2021000147A/es unknown
- 2021-09-08 US US17/468,794 patent/US20210401850A1/en not_active Abandoned
-
2022
- 2022-03-03 JP JP2022032464A patent/JP2022071126A/ja active Pending
-
2023
- 2023-04-04 JP JP2023060638A patent/JP2023085431A/ja active Pending
-
2024
- 2024-02-16 CY CY20241100135T patent/CY1126771T1/el unknown
- 2024-05-31 LT LTPA2024516C patent/LTC3494972I2/lt unknown
- 2024-05-31 FI FIC20240016C patent/FIC20240016I1/fi unknown
- 2024-06-03 HU HUS2400017C patent/HUS2400017I1/hu unknown
- 2024-06-04 LU LU00346C patent/LUC00346I2/fr unknown
- 2024-06-04 CY CY2024017C patent/CY2024017I2/el unknown
- 2024-06-06 FR FR24C1024C patent/FR24C1024I2/fr active Active
- 2024-10-01 US US18/903,013 patent/US20250017939A1/en active Pending
-
2025
- 2025-06-02 JP JP2025091741A patent/JP2025131664A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02312B (me) | DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE | |
| BR112014003225A2 (pt) | profármacos de treprostinil ligados a veículo | |
| HRP20171512T1 (hr) | Derivati betulina | |
| ECSP13012668A (es) | Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso | |
| HRP20150770T1 (hr) | Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| WO2015042497A3 (en) | Substituted aminopyrimidine compounds and methods of use | |
| NZ609527A (en) | N1/n2-lactam acetyl-coa carboxylase inhibitors | |
| NZ703341A (en) | Compositions comprising apomorphine and organic acids and uses thereof | |
| WO2012162254A8 (en) | Inhibitors of lrrk2 kinase activity | |
| HRP20160203T1 (hr) | Pripravci koji sadrže 15-hepe i postupci njihove upotrebe | |
| WO2012048129A3 (en) | Inhibitors of polo-like kinase | |
| GEP20166483B (en) | Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament | |
| EA201400067A1 (ru) | Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента | |
| EA201171087A1 (ru) | СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ | |
| IL220318A (en) | Aqueous solutions comprising 3-quinuclidinones for the treatment of hyperproliferative, autoimmune and heart diseases | |
| ME02405B (me) | Spojevi pirazola као inhibitori sglt1 | |
| HK1216839A1 (zh) | 调整释放制剂 | |
| BR112012019515A2 (pt) | indutor de continuação de leitura, e agente terapêutico para doenças genéticas do tipo de mutações anti-senso | |
| EA201270653A1 (ru) | Антагонист dpи его применение | |
| JP2014518280A5 (me) | ||
| NZ606236A (en) | Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease | |
| MX2015007885A (es) | Compuestos farmaceuticos. | |
| ATE534382T1 (de) | Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon | |
| HRP20130983T1 (hr) | Derivati arilciklopropilacetamida, korisni kao aktivatori glukokinaze |